Tags

Type your tag names separated by a space and hit enter

Antioxidants for Alzheimer disease: a randomized clinical trial with cerebrospinal fluid biomarker measures.
Arch Neurol. 2012 Jul; 69(7):836-41.AN

Abstract

OBJECTIVE

To evaluate whether antioxidant supplements presumed to target specific cellular compartments affected cerebrospinal fluid (CSF) biomarkers.

DESIGN

Double-blind, placebo-controlled clinical trial.

SETTING

Academic medical centers.

PARTICIPANTS

Subjects with mild to moderate Alzheimer disease.

INTERVENTION

Random assignment to treatment for 16 weeks with 800 IU/d of vitamin E (α-tocopherol) plus 500 mg/d of vitamin C plus 900 mg/d of α-lipoic acid (E/C/ALA); 400 mg of coenzyme Q 3 times/d; or placebo.

MAIN OUTCOME MEASURES

Changes from baseline to 16 weeks in CSF biomarkers related to Alzheimer disease and oxidative stress, cognition (Mini-Mental State Examination), and function (Alzheimer's Disease Cooperative Study Activities of Daily Living Scale).

RESULTS

Seventy-eight subjects were randomized; 66 provided serial CSF specimens adequate for biochemical analyses. Study drugs were well tolerated, but accelerated decline in Mini-Mental State Examination scores occurred in the E/C/ALA group, a potential safety concern. Changes in CSF Aβ42, tau, and P-tau(181) levels did not differ between the 3 groups. Cerebrospinal fluid F2-isoprostane levels, an oxidative stress biomarker, decreased on average by 19% from baseline to week 16 in the E/C/ALA group but were unchanged in the other groups.

CONCLUSIONS

Antioxidants did not influence CSF biomarkers related to amyloid or tau pathology. Lowering of CSF F2-isoprostane levels in the E/C/ALA group suggests reduction of oxidative stress in the brain. However, this treatment raised the caution of faster cognitive decline, which would need careful assessment if longer-term clinical trials are conducted.

TRIAL REGISTRATION

clinicaltrials.gov Identifier: NCT00117403.

Links

PMC Free PDF
PMC Free Full Text
Publisher Full Text
Aggregator Full Text

Authors+Show Affiliations

Galasko DR
Department of Neurosciences, University of California, San Diego, 92093, USA. dgalasko@ucsd.edu
Peskind E
No affiliation info available
Clark CM
No affiliation info available
Quinn JF
No affiliation info available
Ringman JM
No affiliation info available
Jicha GA
No affiliation info available
Cotman C
No affiliation info available
Cottrell B
No affiliation info available
Montine TJ
No affiliation info available
Thomas RG
No affiliation info available
Aisen P
No affiliation info available
Alzheimer’s Disease Cooperative Study
No affiliation info available

MeSH

Activities of Daily LivingAgedAged, 80 and overAlzheimer DiseaseAmyloid beta-PeptidesAntioxidantsAscorbic AcidBiomarkersCholinesterase InhibitorsDietary SupplementsDouble-Blind MethodF2-IsoprostanesFemaleFollow-Up StudiesHumansMaleMemantineMental Status ScheduleMiddle AgedPeptide FragmentsRetrospective StudiesThioctic AcidUbiquinonealpha-Tocopheroltau Proteins

Pub Type(s)

Journal Article
Randomized Controlled Trial
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, Non-P.H.S.

Language

eng

PubMed ID

22431837

Clinical Trial Links

Clinical trial which this article describes

Citation

Galasko, Douglas R., et al. "Antioxidants for Alzheimer Disease: a Randomized Clinical Trial With Cerebrospinal Fluid Biomarker Measures." Archives of Neurology, vol. 69, no. 7, 2012, pp. 836-41.
Galasko DR, Peskind E, Clark CM, et al. Antioxidants for Alzheimer disease: a randomized clinical trial with cerebrospinal fluid biomarker measures. Arch Neurol. 2012;69(7):836-41.
Galasko, D. R., Peskind, E., Clark, C. M., Quinn, J. F., Ringman, J. M., Jicha, G. A., Cotman, C., Cottrell, B., Montine, T. J., Thomas, R. G., & Aisen, P. (2012). Antioxidants for Alzheimer disease: a randomized clinical trial with cerebrospinal fluid biomarker measures. Archives of Neurology, 69(7), 836-41.
Galasko DR, et al. Antioxidants for Alzheimer Disease: a Randomized Clinical Trial With Cerebrospinal Fluid Biomarker Measures. Arch Neurol. 2012;69(7):836-41. PubMed PMID: 22431837.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Antioxidants for Alzheimer disease: a randomized clinical trial with cerebrospinal fluid biomarker measures. AU - Galasko,Douglas R, AU - Peskind,Elaine, AU - Clark,Christopher M, AU - Quinn,Joseph F, AU - Ringman,John M, AU - Jicha,Gregory A, AU - Cotman,Carl, AU - Cottrell,Barbara, AU - Montine,Thomas J, AU - Thomas,Ronald G, AU - Aisen,Paul, AU - ,, PY - 2012/3/21/entrez PY - 2012/3/21/pubmed PY - 2012/12/10/medline SP - 836 EP - 41 JF - Archives of neurology JO - Arch Neurol VL - 69 IS - 7 N2 - OBJECTIVE: To evaluate whether antioxidant supplements presumed to target specific cellular compartments affected cerebrospinal fluid (CSF) biomarkers. DESIGN: Double-blind, placebo-controlled clinical trial. SETTING: Academic medical centers. PARTICIPANTS: Subjects with mild to moderate Alzheimer disease. INTERVENTION: Random assignment to treatment for 16 weeks with 800 IU/d of vitamin E (α-tocopherol) plus 500 mg/d of vitamin C plus 900 mg/d of α-lipoic acid (E/C/ALA); 400 mg of coenzyme Q 3 times/d; or placebo. MAIN OUTCOME MEASURES: Changes from baseline to 16 weeks in CSF biomarkers related to Alzheimer disease and oxidative stress, cognition (Mini-Mental State Examination), and function (Alzheimer's Disease Cooperative Study Activities of Daily Living Scale). RESULTS: Seventy-eight subjects were randomized; 66 provided serial CSF specimens adequate for biochemical analyses. Study drugs were well tolerated, but accelerated decline in Mini-Mental State Examination scores occurred in the E/C/ALA group, a potential safety concern. Changes in CSF Aβ42, tau, and P-tau(181) levels did not differ between the 3 groups. Cerebrospinal fluid F2-isoprostane levels, an oxidative stress biomarker, decreased on average by 19% from baseline to week 16 in the E/C/ALA group but were unchanged in the other groups. CONCLUSIONS: Antioxidants did not influence CSF biomarkers related to amyloid or tau pathology. Lowering of CSF F2-isoprostane levels in the E/C/ALA group suggests reduction of oxidative stress in the brain. However, this treatment raised the caution of faster cognitive decline, which would need careful assessment if longer-term clinical trials are conducted. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT00117403. SN - 1538-3687 UR - https://www.unboundmedicine.com/medline/citation/22431837/full_citation L2 - https://jamanetwork.com/journals/jamaneurology/fullarticle/10.1001/archneurol.2012.85 DB - PRIME DP - Unbound Medicine ER -